Adenosine

Adenosine

SCHEMBL3296155

NC(N)=O.Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.O=P(O)(O)O

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3

The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 known ✓ P0DMS8 4/20 0.83
ADORA1 known ✓ P30542 3/20 0.83
ADORA2A known ✓ P29274 1/20 0.83
ADORA2B known ✓ P29275 1/20 0.83
SMN1; SMN2 Q16637 3/20 0.83
DPP4 P27487 1/20 0.83
MEN1 O00255 1/20 0.83
SLC28A1 O00337 1/20 0.83
MAP3K7 O43318 1/20 0.83
SLC28A2 O43868 1/20 0.83
GAPDH P04406 1/20 0.83
MAPK1 P28482 1/20 0.83
STAT6 P42226 1/20 0.83
PI4KA P42356 1/20 0.83
KMT2A Q03164 1/20 0.83
PI4K2B Q8TCG2 1/20 0.83
DOT1L Q8TEK3 1/20 0.83
SLC29A1 Q99808 1/20 0.83
PI4K2A Q9BTU6 1/20 0.83
SLC28A3 Q9HAS3 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenosine SCHEMBL6242700 0.97 ADORA1 (0.89) ADORA3ADORA1SMN1; SMN2DPP4MEN1
Vidarabine SCHEMBL7103173 0.97 ADORA1 (0.89) ADORA3ADORA1SMN1; SMN2DPP4MEN1
Adenosine SCHEMBL459769 0.97 ADORA1 (0.89) ADORA3ADORA1SMN1; SMN2DPP4MEN1
Adenosine SCHEMBL468212 0.97 ADORA1 (0.89) ADORA3ADORA1SMN1; SMN2DPP4MEN1
Adenosine SCHEMBL3031964 0.97 ADORA1 (0.89) ADORA3ADORA1SMN1; SMN2DPP4MEN1
Adenosine SCHEMBL50788 0.97 ADORA1 (0.89) ADORA3ADORA1SMN1; SMN2DPP4MEN1
Adenosine SCHEMBL1746637 0.97 ADORA1 (0.89) ADORA3ADORA1SMN1; SMN2DPP4MEN1
Adenosine SCHEMBL1744578 0.97 ADORA1 (0.89) ADORA3ADORA1SMN1; SMN2DPP4MEN1
Adenosine SCHEMBL3046213 0.97 ADORA1 (0.89) ADORA3ADORA1SMN1; SMN2DPP4MEN1
Adenosine SCHEMBL9171507 0.97 ADORA1 (0.89) ADORA3ADORA1SMN1; SMN2DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741473-B2 Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles INSPIRE PHARMACEUTICALS, INC. (US) 2010-06-22 US disclosed
EP-1863826-A1 PROCESS FOR THE PREPARATION OF 4,6-DISUBSTITUTED-TETRAHYDRO-FURO, THIENO, PYRROLO AND CYCLOPENTA-[3,4][1,3]DIOXOLES Inspire Pharmaceuticals, Inc. (US) 2007-12-12 EP disclosed
US-20060234976-A1 Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles INSPIRE PHARMACEUTICALS, INC. 2006-10-19 US disclosed
WO-2006105529-A1 PROCESS FOR THE PREPARATION OF 4,6-DISUBSTITUTED-TETRAHYDRO-FURO, THIENO, PYRROLO AND CYCLOPENTA-[3,4][1,3]DIOXOLES INSPIRE PHARMACEUTICALS, INC. (US) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060234976-A1 Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles THPO, F2, PF4 ADORA3 512/4885ADORA1 712/4885ADORA2A 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.